Glenmark introduces medication to prevent chemotherapy-induced nausea

The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/62de0Mm
via IFTTT